

Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 1523691, 9 pages
<http://dx.doi.org/10.1155/2016/1523691>



Research Article

Investigation of Calcium Channel Blockers as Antiprotozoal Agents and Their Interference in the Metabolism of *Leishmania (L.) infantum*

Juliana Quero Reimão,^{1,2} Juliana Tonini Mesquita,¹
Daiane Dias Ferreira,¹ and Andre Gustavo Tempone¹

¹Centre for Parasitology and Mycology, Institute Adolfo Lutz, Secretary of Health of São Paulo State, Avenida Dr. Arnaldo 351, 01246-000 São Paulo, SP, Brazil

²Departamento de Morfologia e Patologia Básica, Faculdade de Medicina de Jundiaí, Rua Francisco Telles 250, 13202-550 Jundiaí, SP, Brazil

Correspondence should be addressed to Andre Gustavo Tempone; atempone@usp.br

Received 28 October 2015; Accepted 24 December 2015

Academic Editor: Juntra Karbwang

Copyright © 2016 Juliana Quero Reimão et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Leishmaniasis and Chagas disease are neglected parasitic diseases endemic in developing countries; efforts to find new therapies remain a priority. Calcium channel blockers (CCBs) are drugs in clinical use for hypertension and other heart pathologies. Based on previous reports about the antileishmanial activity of dihydropyridine-CCBs, this work aimed to investigate whether the *in vitro* anti-*Leishmania infantum* and anti-*Trypanosoma cruzi* activities of this therapeutic class would be shared by other non-dihydropyridine-CCBs. Except for amrinone, our results demonstrated antiprotozoal activity for fendiline, mibefradil, and lidoflazine, with IC_{50} values in a range between 2 and 16 μ M and Selectivity Index between 4 and 10. Fendiline demonstrated depolarization of mitochondrial membrane potential, with increased reactive oxygen species production in amlodipine and fendiline treated *Leishmania*, but without plasma membrane disruption. Finally, *in vitro* combinations of amphotericin B, miltefosine, and pentamidine against *L. infantum* showed in isobolograms an additive interaction when these drugs were combined with fendiline, resulting in overall mean sum of fractional inhibitory concentrations between 0.99 and 1.10. These data demonstrated that non-dihydropyridine-CCBs present antiprotozoal activity and could be useful candidates for future *in vivo* efficacy studies against Leishmaniasis and Chagas' disease.

1. Introduction

Leishmaniasis is a neglected infectious disease caused by several different species of protozoan parasites of the genus *Leishmania*. It affects 12 million people in 98 countries and territories and is mainly associated with poverty in developing nations. Current strategies to control this disease are mainly based on chemotherapy. Despite being available for the last 100 years, the chemotherapy is based on the use of few drugs, including the antimonial derivatives. High costs of treatment, elevated toxicity, parenteral administration, and the emergence of resistance are the main drawbacks [1].

Considering the few therapeutic options and lack of interest from private sector, the need for novel drugs is evident [2].

Calcium channel blockers (CCBs) are a class of drugs that act by selective inhibition of calcium influx through cellular membranes. They are among the most widely used drugs in cardiovascular medicine with roles not only in hypertension but also in angina and (for some CCBs) tachyarrhythmias [3]. Although often considered as a single class, CCBs can be subdivided into the following groups depending on chemical structure: dihydropyridines (e.g., nifedipine, nimodipine, and amlodipine), the benzothiazepines (e.g., diltiazem), and phenylalkylamines (e.g., verapamil) [4].

Dihydropyridines have been considered promising antiparasitic hits, especially against protozoan parasites. The *in vivo* oral efficacy of amlodipine and lacidipine has been shown in the treatment of *Leishmania (L.) donovani* infected mice [5]. Additionally, the *in vitro* antiparasitic activity of eight clinically used dihydropyridines (azelnidipine, amlodipine, cilnidipine, lercanidipine, nicardipine, nifedipine, nimodipine, and nitrendipine) was demonstrated against a panel of *Leishmania* species and *Trypanosoma cruzi* [6, 7].

Based on previous reports about the antileishmanial activity of dihydropyridines, this work investigated the antiparasitic potential of other non-dihydropyridine-CCBs. For this, the *in vitro* activity of four non-dihydropyridine agents (amrinone, fendiline, mibefradil, and lidoflazine) was tested against different *Leishmania* species and their cytotoxicity to mammalian cells was evaluated. We also investigated the mechanism of action (MoA) involved with the antileishmanial activity of fendiline and the *in vitro* effect of its combination with antileishmanial standard drugs.

2. Material and Methods

2.1. Drugs and Chemicals. Dimethyl sulfoxide (DMSO), phosphate buffer saline (PBS), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, thiazol blue), sodium dodecyl sulfate (SDS), RPMI-1640 medium, and M199 medium were purchased from Sigma (St. Louis, MO, USA). Amrinone, fendiline, lidoflazine, and mibefradil were purchased from Sigma (St. Louis, MO, USA). Pentamidine was from Sideron. Pentavalent antimony (Glucantime®) and amlodipine were kindly donated by Bayer (Brazil). Other analytical reagents were purchased from Sigma unless otherwise stated.

2.2. Experimental Animals. Golden hamsters and BALB/c mice were supplied by the animal breeding facility at the Adolfo Lutz Institute of São Paulo. They were maintained in sterilized cages under a controlled environment and received water and food *ad libitum*. Golden hamsters were infected each month with amastigotes from the spleen to maintain the strain of *L. (L.) infantum*. BALB/c mice were used for obtaining peritoneal macrophages. Animal procedures were performed with the approval of the Research Ethics Commission, in agreement with the Guidelines for the Care and Use of Laboratory Animals from the National Academy of Sciences.

2.3. Parasites and Macrophages. Promastigotes of *L. (L.) amazonensis* (WHO/BR/00/LT0016), *L. (V.) braziliensis* (MHO/BR/75/M2903), and *L. (L.) infantum* (MHOM/BR/1972/LD) [synonymous with *L. (L.) chagasi*] were maintained in M199 medium supplemented with 10% calf serum and 0.25% hemin at 24°C. *L. (L.) infantum* amastigotes were obtained from the spleen of infected hamster by differential centrifugation at the 60–70th days after infection. Macrophages were collected from the peritoneal cavity of BALB/c mice by washing with RPMI-1640 medium supplemented with 10% fetal calf serum and were maintained at 37°C in a 5% CO₂ humidified

incubator. *Trypanosoma cruzi* trypomastigotes (Y strain) were maintained in LLC-MK2 (ATCC CCL 7) cells using RPMI-1640 medium supplemented with 2% calf serum at 37°C in a 5% CO₂ humidified incubator.

2.4. Determination of the In Vitro Antileishmanial Activity. To determine the 50% inhibitory concentration (IC₅₀) against *Leishmania* promastigotes, the drugs were dissolved in DMSO and diluted with M199 medium in 96-well microplates, with 100 μM as the highest concentration. Each drug was tested twice at eight concentrations prepared in twofold dilutions. Promastigotes were counted in a Neubauer hemocytometer and seeded at 1 × 10⁶ parasites/well with a final volume of 150 μL. Controls with DMSO and without drugs were performed. Pentamidine was used as a standard drug. The plate was incubated for 24 hours at 24°C and the viability of promastigotes was verified by the MTT assay. Briefly, MTT (5 mg/mL) was dissolved in PBS, sterilized through 0.22 μm membrane and 20 μL/well was added, for 4 hours at 24°C. Promastigotes were incubated without compounds and used as a viability control. Formazan extraction was performed using 10% SDS for 18 hours (80 μL/well) at 24°C, and the optical density was determined in a Multiskan MS (UNISCIENCE) plate reader at 550 nm. The 100% viability was expressed based on the optical density of control promastigotes, after normalization. To determine the IC₅₀ value against *L. (L.) infantum* intracellular amastigotes, peritoneal macrophages were collected from the peritoneal cavity of BALB/c as described above, and added to 16-well chamber slides (Lab-Tek-NUNC®) at 5 × 10⁴ cells/well. Plates were incubated at 37°C in a 5% CO₂ humidified incubator for 24 hours. *L. (L.) infantum* amastigotes extracted from spleens and separated by differential centrifugation were added to macrophages at a ratio of 10:1 (amastigotes:macrophage). After 24 hours, extracellular parasites were removed by washing, fresh medium containing the drugs and controls was added, and the cells were incubated at 37°C for a period of 120 hours. Further medium changes with fresh drugs were carried out after 72 hours. At the end of the assay, the slides were stained with Giemsa and observed using light microscopy. Glucantime was used as a standard drug. The IC₅₀ was determined by the number of infected macrophages in 400 cells.

2.5. Determination of the Antitrypanosomal Activity. To determine the IC₅₀ against *T. cruzi* trypomastigotes, drugs were dissolved in DMSO and diluted with RPMI-1460 medium in 96-well microplates, with the highest concentration at 100 μM. Trypomastigotes obtained from LLC-MK2 cultures were counted in a Neubauer hemocytometer and seeded at 1 × 10⁶ parasites/well in 96-well microplates. Test drugs were incubated for 24 hours at 37°C in a 5% CO₂ humidified incubator and the viability of trypomastigotes was verified by the MTT assay as described above. Benznidazole was used as a standard drug.

2.6. Cytotoxicity in Mammalian Cells. LLC-MK2 were seeded at 5 × 10⁴ cells/well in 96-well microplates and incubated with

drugs with 200 μM as the highest concentration, for 48 hours at 37°C in a 5% CO_2 humidified incubator. The viability of the cells was determined by the MTT assay as described above. Control cells were incubated in the presence of DMSO and without drugs. Viability of 100% was expressed based on the optical density of control LLC-MK2 cells, after normalization. The Selectivity Index (SI) was given by the ratio between the cytotoxicity in LLC-MK2 cells and the antiparasitic activity.

2.7. Investigation of Mitochondrial Membrane Potential. *L. (L.) infantum* promastigotes were washed with PBS and deposited on a 96-well microplate (2×10^6 cells/well) and incubated with amlodipine or fendiline (20 μM) for 60 minutes at 24°C. Then MitoTracker® Red CM-H₂XROS (500 nM) was added and the incubation was continued for 40 minutes in the dark. Cells were washed twice with HBSS (Hanks Balanced Salt Solution) and the fluorescence was measured using a fluorimetric microplate reader (FilterMax F5 Multi-Mode Microplate Reader-Molecular Devices) with excitation and emission wavelengths of 540 and 595 nm, respectively [8]. Nitazoxanide (60 $\mu\text{g}/\text{mL}$) was used as a positive control [9] and untreated promastigotes were used as negative control.

2.8. Analysis of Reactive Oxygen Species (ROS). *L. (L.) infantum* promastigotes (2×10^6 cells/well) were washed in HBSS medium and incubated with amlodipine or fendiline (20 μM) for 60 minutes at 24°C. To these cells 2',7'-dichlorodihydrofluorescein diacetate (H₂DCF-DA) was added (5 μM) and incubation was prolonged for 15 minutes. Then the fluorescence was measured using a fluorimetric microplate reader (FilterMax F5 Multi-Mode Microplate Reader-Molecular Devices) with excitation and emission wavelengths of 485 and 520 nm, respectively. Nitazoxanide (60 $\mu\text{g}/\text{mL}$) was used as positive control [9] and untreated promastigotes were used as negative control.

2.9. Evaluation of the Permeability of the Cell Membrane. *L. (L.) infantum* promastigotes were washed with PBS, deposited on a 96-well microplate (2×10^6 parasites/well) and incubated with SYTOX® Green (1 μM) for 15 minutes at 24°C [10]. Amlodipine and fendiline were added at 20 μM and the fluorescence was measured up to 60 minutes. The fluorescence intensity was determined using a fluorimetric microplate reader (FilterMax F5 Multi-Mode Microplate Reader-Molecular Devices) with excitation and emission wavelengths of 485 and 520 nm, respectively. Triton X-100 (0.1%) was used as positive control and untreated promastigotes were used as negative control.

2.10. Determination of Drug Interactions. The interactions between drugs were *in vitro* evaluated by modified isobologram method [11, 12]. Fendiline was *in vitro* combined with amphotericin B, miltefosine, and pentamidine. IC₅₀ values of individual drugs were obtained against *L. (L.) infantum* promastigotes as described above. These values were used to determine the maximum concentrations of each drug in the combination assay, assuring the IC₅₀ in the fourth point of the serial dilution [11]. The highest concentrations of the solutions were prepared in proportions of 5:0, 4:1,

3:2, 2:3, 1:4, and 0:5 of fendiline and partner drug, respectively, which were serially diluted to the seventh well of the microplate in two intercalated serial dilutions (base 2).

2.11. Determination of FIC Index, Isobologram Construction, and Classification of the Nature of Interaction. Fifty and ninety % fractional inhibitory concentrations (FIC₅₀ and FIC₉₀, resp.) and sum of FIC ($\sum\text{FIC}$) were calculated as follows: FIC₅₀ and FIC₉₀ of drug A = IC₅₀ and IC₉₀ of drug A in combination/IC₅₀ and IC₉₀ of drug A alone. The same equation was applied to the partner drug (drug B). Sum of FIC₅₀ and FIC₉₀ ($\sum\text{FIC}_{50}$ and $\sum\text{FIC}_{90}$) was calculated as follows: FIC₅₀ and FIC₉₀ drug A + FIC₅₀ and FIC₉₀ drug B. An overall mean $\sum\text{FIC}_{50}$ and $\sum\text{FIC}_{90}$ ($x \sum\text{FIC}_{50}$ and $x \sum\text{FIC}_{90}$) were calculated for each combination and used to classify the nature of interaction as follows: synergy ($x \sum\text{FIC}_{50}$ and $x \sum\text{FIC}_{90} \leq 0.5$), additivity ($x \sum\text{FIC}_{50}$ and $x \sum\text{FIC}_{90}$ between >0.5 and ≤ 4), and antagonism ($x \sum\text{FIC}_{50}$ and $x \sum\text{FIC}_{90} > 4$) [13]. Isobolograms were constructed based on FIC₅₀ and FIC₉₀ [14] for each component of a dosage combination.

2.12. Statistical Analysis. The IC₅₀ values were calculated using sigmoidal dose-response curves in GraphPad Prism 5.0 software. The data obtained represented the mean and standard deviation of at least two independent assays performed in duplicate or triplicate. One-way ANOVA followed by the Tukey post-test was used for significance testing ($p < 0.05$) for all assays.

3. Results

3.1. Antileishmanial and Antitrypanosomal Activity of CCBs and Cytotoxicity to Mammalian Cells. Amrinone, fendiline, lidoflazine, and mibefradil were incubated with *Leishmania* spp. promastigotes, intracellular amastigotes, and *T. cruzi* trypomastigotes to evaluate their *in vitro* antiparasitic activity. Fendiline, lidoflazine, and mibefradil showed IC₅₀ values ranging from 2.75 to 16.15 μM against *Leishmania* spp. promastigotes. Mibefradil was the most active compound against promastigotes, while amrinone showed lack of antileishmanial activity to the highest tested concentration of 100 μM . Pentamidine was used as a standard drug in the promastigotes assay and resulted in IC₅₀ values ranging from 0.69 to 1.14 μM (Table 1).

The activity of fendiline and lidoflazine against intracellular amastigotes of *L. (L.) infantum* resulted in IC₅₀ values ranging from 12 to 16 μM . Although mibefradil was the most active compound against promastigotes, it showed lack of activity against *L. (L.) infantum* intracellular amastigotes (Table 1).

The antitrypanosomal activity was also examined and fendiline, lidoflazine, and mibefradil presented IC₅₀ values, ranging from 2 to 12 μM . Mibefradil was the most active drug, while amrinone was inactive. These tested compounds were considerably more effective than the standard drug benznidazole, which showed an IC₅₀ of 440 μM (Table 1).

In order to evaluate the cytotoxicity against mammalian cells, the tested compounds were incubated with LLC-MK2

TABLE 1: Effect of CCBs and standard drugs on parasites and mammalian cells.

Drug	IC ₅₀ (μM) ± SD ^a					
	<i>L. (L.) infantum</i> promastigotes	<i>L. (L.) infantum</i> amastigotes	<i>L. (L.) amazonensis</i> promastigotes	<i>L. (V.) braziliensis</i> promastigotes	<i>T. cruzi</i> trypomastigotes	LLC-MK2 cytotoxicity
Amrinone	ne ^b	ne ^b	ne ^b	ne ^b	ne ^b	>500
Fendiline	16.15 ± 4.20	12.20 ± 1.74	8.66 ± 1.27	9.15 ± 0.78	12.13 ± 2.97	49.85 ± 8.16
Lidoflazine	17.67 ± 0.93	16.29 ± 4.45	11.54 ± 1.49	14.48 ± 1.08	10.39 ± 1.87	106.54 ± 57.99
Mibefradil	3.60 ± 0.11	ne ^b	2.23 ± 0.42	2.75 ± 0.39	2.99 ± 0.43	11.96 ± 1.03
Pentamidine	1.06 ± 0.12	nd ^c	1.14 ± 0.15	0.69 ± 0.04	nd ^c	23.48 ± 3.53
Glucantime ^d	nd ^c	30.15 ± 1.18	nd ^c	nd ^c	nd ^c	>500
Benznidazole	nd ^c	nd ^c	nd ^c	nd ^c	440.18 ± 39.14	>500

^aIC50: 50% inhibitory concentration ± standard deviation (SD).

^bne: not effective.

^cnd: not determined.

^dConcentrations for Glucantime are expressed as μg/mL, as the molecular weight is unknown.

TABLE 2: Selectivity Index (SI) of CCBs, given by the ratio between the cytotoxicity to LLC-MK2 cells and the antiparasitic activity.

Drug	<i>L. (L.) infantum</i> amastigotes	<i>T. cruzi</i> trypomastigotes
Amrinone	nd ^a	nd ^a
Fendiline	4.09	4.11
Lidoflazine	6.54	10.25
Mibefradil	nd ^a	4.01

^and: not determined.

cells, resulting in IC₅₀ values ranging from 11 to 106 μM (Table 1).

The Selectivity Index (SI) of tested compounds was calculated by the ratio between the cytotoxicity to LLC-MK2 cells and the antiparasitic activity. The tested compounds presented SI values ranging from 4 to 6 for *L. (L.) infantum* amastigotes and from 4 to 10 for *T. cruzi* trypomastigotes (Table 2).

3.2. Action of Amlodipine and Fendiline in the Mitochondrial Membrane Potential. The effect of amlodipine and fendiline on the *L. (L.) infantum* mitochondrial membrane potential was evaluated in promastigotes using the fluorescent dye MitoTracker Red. Amlodipine and fendiline significantly ($p < 0.05$) affected the mitochondrial membrane potential of *L. (L.) infantum*, reducing the fluorescence levels by 7 and 18%, respectively, relative to untreated parasites. Nitazoxanide was used as positive control and resulted in a strong reduction of fluorescence intensity (Figure 1).

3.3. Generation of Reactive Oxygen Species (ROS) upon Treatment with Amlodipine or Fendiline. The regulation of ROS levels was examined using the fluorescent probe 2',7'-dichlorodihydrofluorescein diacetate (H₂DCF-DA) after incubation with the drugs. Amlodipine and fendiline promoted an intense and significant ($p < 0.05$) upregulation




FIGURE 1: Action of amlodipine and fendiline in the mitochondrial membrane potential. Alterations in mitochondrial membrane potential were evaluated in *L. (L.) infantum* promastigotes after treatment with amlodipine and fendiline (20 μM), using the fluorescent probe MitoTracker Red. Untreated parasites were used as negative control, while parasites treated with nitazoxanide were used as positive control. (*) indicates significant difference relative to the untreated group ($*p < 0.05$; $**p < 0.001$).

of ROS content when compared to untreated parasites (Figure 2). Amlodipine induced almost 3-fold higher ROS levels in *L. (L.) infantum* when compared to fendiline. Nitazoxanide was used as positive control and resulted in significant upregulation of ROS relative to untreated parasites, as previously reported [9]. Amlodipine presented 1.99-fold higher upregulation of ROS than nitazoxanide (Figure 2).

3.4. Effect of Amlodipine and Fendiline on Plasma Membrane Permeability of *L. (L.) infantum*. In order to evaluate if the mitochondrial dysfunction was a result of any alteration in




FIGURE 2: ROS generation in promastigotes in the presence of amlodipine and fendiline. The ROS production was verified using the indicator 2',7'-dichlorodihydrofluorescein diacetate (H₂DCF-DA) after incubation with amlodipine and fendiline (20 μ M). Nitazoxanide was used as positive control. (*) indicates significant difference relative to the untreated group (* $p < 0.05$; ** $p < 0.001$; *** $p < 0.001$).

plasma membrane, amlodipine and fendiline were incubated with *L. (L.) infantum* promastigotes and examined by the fluorescent probe SYTOX Green assay. According to the fluorescence intensity of untreated parasites, both drugs caused no interference on the plasma membrane permeability up to 60-minute incubation (results not shown). Untreated parasites were used as negative control and resulted in no alteration in plasma membrane permeability, while Triton X-100 was used as positive control and resulted in fully permeabilized parasites.

3.5. Combination of Fendiline and Antileishmanial Standard Drugs. The interactions between fendiline and three antileishmanial standard drugs (amphotericin B, miltefosine, and pentamidine) were investigated in *L. (L.) infantum* promastigotes by the modified isobologram method. In order to calculate the FIC₅₀ and FIC₉₀ of both drugs, the IC₅₀ and IC₉₀ of individual drugs were calculated and compared with the IC₅₀ and IC₉₀ values of each association. For each drug combination, $x \sum \text{FIC}_{50}$ and $x \sum \text{FIC}_{90}$ of both drugs were calculated, as shown in Table 3. The combination of fendiline and amphotericin B, miltefosine and pentamidine resulted in $x \sum \text{FIC}_{50}$ and $x \sum \text{FIC}_{90}$ ranging from 0.99 to 1.30, indicating indifferent/additive interaction according to the adopted classification (Table 3).

In order to explore and visualize the combined effect of fendiline and the antileishmanial drugs, isobolograms were constructed based on the FIC₅₀ and FIC₉₀ values of each combination (Figure 3). The additive isobole was indicated by a straight dotted line intercepting the axes, when FIC = 1. Points corresponding to the FIC₅₀ and FIC₉₀ values of each combination were connected by a tendency line. Thus, it is noted that all points are located slightly above or below

TABLE 3: Effect of combination of fendiline and antileishmanial standard drugs in *L. (L.) infantum* promastigotes.

Combination	$x \sum \text{FIC}_{50}$ ^a	$x \sum \text{FIC}_{90}$ ^a
Fendiline + amphotericin B	1.18	0.99
Fendiline + miltefosine	1.30	1.02
Fendiline + pentamidine	1.22	1.10

^aOverall mean sum.

the additive isobole, close to the range that classifies these interactions as indifferent/additive.

4. Discussion

The search for new, safe, and cost-benefit therapies against Leishmaniasis and Chagas' disease remains a priority for developing nations. Drug repositioning or repurposing has been a successful approach for neglected diseases [15, 16].

Calcium channel blockers in clinical use for hypertension and heart diseases have been considered privileged structures, demonstrating a wide range of promising biological activities, among them, *in vivo* experimental efficacy against Ebola virus [17], *in vitro* activity against filovirus [18], and also against protozoan parasites as *Leishmania* [12], *T. cruzi* [7, 19–21], and *Plasmodium* [22, 23].

In the present work, the *in vitro* activity of fendiline and lidoflazine against *Leishmania* spp. promastigotes, *T. cruzi* trypomastigotes, and *L. (L.) infantum* intracellular amastigotes was demonstrated. Mibefradil also presented activity against *Leishmania* spp. promastigotes and *T. cruzi* trypomastigotes but was ineffective against intracellular amastigotes, probably due to metabolic differences between the extracellular and intracellular parasites or even to poor penetration of the drug into the host cells. This is the first report of antiprotozoal activity of these compounds which are non-dihydropyridine-CCBs. In a previous work, the dihydropyridines isradipine and lacidipine demonstrated *in vitro* activity against *T. cruzi* epimastigotes, with IC₅₀ values of 20 and 33 μ M, respectively [20] showing a similar activity to fendiline and lidoflazine against *T. cruzi* trypomastigotes in the present study.

Otherwise, amrinone, a positive inotropic cardiotoxic with vasodilator properties, showed lack of activity against *Leishmania* spp. and *T. cruzi*. This result suggests that the antiparasitic activity of CCBs is rather ascribed to the chemical structure of individual compounds than to the CCB properties. Conversely, another closely related compound used as a potassium channel blocker, 4-aminopyridine, exhibited activity against *L. (L.) amazonensis*, with an IC₅₀ value of 46 μ M, but also lacked activity against *L. (L.) major* (IC₅₀ > 400 μ M) [24].

The mode of action of CCBs involves the blockage of calcium ions movement through calcium channels [3]. Calcium ions play an important role in regulation of many vital functions. By penetrating the cell, they activate bioenergetic processes, as the transformation of ATP into cyclic AMP and protein phosphorylation. In high concentrations, calcium ions cause different destructive changes [25].




FIGURE 3: Isobolograms constructed based on the combined effect of fendiline and the antileishmanial drugs. Isobolograms generated based on FIC₅₀ (left side) and FIC₉₀ (right side) values showing the interaction between fendiline and antileishmanial standard drugs against *L. (L.) infantum* promastigotes. Fendiline plus amphotericin B (a and b), miltefosine (c and d), and pentamidine (e and f). The dotted line corresponds to the predicted position of the experimental points for a simple additive effect and points corresponding to the FIC values were connected by a tendency line.

The presence of a voltage gated calcium channel sharing several characteristics with the human counterpart has been recently demonstrated in the plasma membrane of *Leishmania* [26]; then interference of CCBs in calcium channels of treated parasites cannot be ruled out.

In a previously published work, nimodipine, a dihydropyridine, has exhibited *in vitro* activity against *L. (L.) infantum*, causing extensive mitochondrial damage in treated parasites, as observed by transmission electron microscopy [6]. In our

study, fendiline demonstrated the higher potency against *Leishmania* amastigotes and it was selected for the investigation of the mechanism of action and drug combination assays. For comparisons, amlodipine, a dihydropyridine-CCB, with previously reported activity against *Leishmania* parasites [7], was included in the assays. Amlodipine presented IC₅₀ values against *Leishmania* spp. close to mibefradil, but about 2- to 3-fold higher potency against *L. (L.) infantum* intracellular amastigotes than fendiline and lidoflazine.

Our data demonstrated that *Leishmania* promastigotes treated with amlodipine and fendiline exhibited reduced ability to concentrate the dye (MitoTracker Red), indicating a collapse of the mitochondrial membrane potential. This result is an indication that the energy-coupling system in the mitochondria is most likely inactivated, leading to parasite death. Another study demonstrated that *Leishmania* promastigotes treated with nimodipine also resulted in strong mitochondrial damage within 60 min incubation [7].

There is inherent relationship between ROS generation and respiratory chain in both mammals and *Leishmania*. The mitochondrial complex III was described as the main source of superoxide anion radicals [27]. Due to the observed effect of fendiline in the mitochondrial membrane potential, we also investigated the ROS levels of parasites treated with fendiline and amlodipine. We observed that depolarization in mitochondrial membrane potential was accompanied by an increase in ROS production when parasites were treated with both drugs. The single mitochondrion is one of the major sources of ROS in trypanosomatids, even under physiological conditions. These reactive species could play different roles in the parasites, involving signaling or cytotoxicity; to control the ROS levels trypanosomatids present mitochondrial antioxidant defenses [28]. The upregulation of ROS in *Leishmania* induced by fendiline and amlodipine might have contributed to a cellular toxicity, leading to an oxidative stress and parasite death.

In order to evaluate whether the fast and strong mitochondrial damage could be ascribed to the ability of amlodipine and fendiline to alter the plasma membrane of *Leishmania*, we investigated the permeability using the fluorescent probe SYTOX Green. Previous ultrastructural observation of nimodipine treated promastigotes revealed plasma membrane blebbing, although no pore forming activity could be observed [6]. In the present work, we observed that treatment with amlodipine and fendiline resulted in lack of significant changes in fluorescence intensity up to 60-minute incubation, suggesting no alteration in permeability levels. Parasites treated with Triton X-100 (positive control) showed early and increased penetration of the dye SYTOX Green and are indicative of membrane rupture.

The effects of several drugs that interfere directly with mitochondrial physiology in parasites such as *Leishmania* have been described. The unique mitochondrial features of *Leishmania* make this organelle an ideal drug target [29]. Taken together, our results demonstrate that amlodipine and fendiline exert their antileishmanial effect on *Leishmania* promastigotes due to the disruption in the mitochondrial function and to the generation of ROS.

Considering the need for new, potent, and safe treatments for Leishmaniasis, the use of monotherapy may not be the ideal future. Drug combinations are used to prevent resistance and increase safety of treatments. It has been widely studied for cancer [30], malaria, and also Leishmaniasis [31, 32]. Previous report demonstrated combinations of four dihydropyridine-CCBs (amlodipine, lercanidipine, nifedipine, and nimodipine) with antileishmanial drugs [12]. Here, we report the combination of a non-dihydropyridine drug, fendiline, with three antileishmanial clinically used drugs.

Drugs given in combination may produce effects that are similar to, higher or smaller than the effect predicted from their individual potencies [33]. Here, we observed that the effect of fendiline associated with amphotericin B, miltefosine, or pentamidine was equivalent, that is, equally effective when each drug was given separately, according to the χ^2 FIC and the isobologram graphic analysis. This behavior was similar to what was previously observed when using dihydropyridines and could be an indication that both dihydropyridine and non-dihydropyridine agents possess similar mode of action on *Leishmania*. However, additional studies are required to confirm this hypothesis.

5. Conclusions

The results of this work extend the investigation of CCBs as antiprotozoal agents and indicate that its leishmanicidal activity is related to mitochondria dysfunction and ROS generation. The combination of any of the drugs used did not show synergistic effects. On the contrary, all the isobolograms indicated indifferent/additive interaction. However, the drug combination assays indicated that the effect of fendiline plus amphotericin B, miltefosine, or pentamidine could be evaluated in future in animal models, since no *in vitro* antagonism was observed in any combination. Earlier, further assays must be conducted in order to verify the efficacy of fendiline in the treatment of *Leishmania* infected animals.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgments



This work was supported by São Paulo Research Foundation (FAPESP 2012/18756-1). The authors also acknowledge the CNPq scientific research award given to Andre Gustavo Tempone and the scholarships given to Juliana Tonini Mesquita (CNPq project number 471458/2012-0 and 132336/2011-1) and to Juliana Quero Reimão (FAPESP 08/11434-3 and 2011/21970-2).

References

- [1] J. P. de Menezes, C. E. Guedes, A. L. Petersen, D. B. Fraga, and P. S. Veras, "Advances in development of new treatment for leishmaniasis," *BioMed Research International*, vol. 2015, Article ID 815023, 11 pages, 2015.
- [2] E. M. Moore and D. N. Lockwood, "Treatment of visceral leishmaniasis," *Journal of Global Infectious Diseases*, vol. 2, no. 2, pp. 151–158, 2010.
- [3] D. R. Abernethy and J. B. Schwartz, "Calcium-antagonist drugs," *The New England Journal of Medicine*, vol. 341, no. 19, pp. 1447–1457, 1999.
- [4] M. Motro, J. Shemesh, and E. Grossman, "Coronary benefits of calcium antagonist therapy for patients with hypertension," *Current Opinion in Cardiology*, vol. 16, no. 6, pp. 349–355, 2001.

- [5] P. Palit and N. Ali, "Oral therapy with amlodipine and lacidipine, 1,4-dihydropyridine derivatives showing activity against experimental visceral leishmaniasis," *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 1, pp. 374–377, 2008.
- [6] A. G. Tempone, N. N. Taniwaki, and J. Q. Reimão, "Antileishmanial activity and ultrastructural alterations of *Leishmania* (L.) *chagasi* treated with the calcium channel blocker nimodipine," *Parasitology Research*, vol. 105, no. 2, pp. 499–505, 2009.
- [7] J. Q. Reimão, M. T. Scotti, and A. G. Tempone, "Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: *in vitro* evaluation and structure-activity relationship study," *Bioorganic and Medicinal Chemistry*, vol. 18, no. 22, pp. 8044–8053, 2010.
- [8] R. A. M. Williams, T. K. Smith, B. Cull, J. C. Mottram, and G. H. Coombs, "ATG5 is essential for ATG8-dependent autophagy and mitochondrial homeostasis in *Leishmania major*," *PLoS Pathogens*, vol. 8, no. 5, Article ID e1002695, 14 pages, 2012.
- [9] J. T. Mesquita, E. G. Pinto, N. N. Taniwaki, A. J. Galisteo Jr., and A. G. Tempone, "Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative stress in *Leishmania* (L.) *infantum*," *Acta Tropica*, vol. 128, no. 3, pp. 666–673, 2013.
- [10] M. L. Mangoni, J. M. Saugar, M. Dellisanti, D. Barra, M. Simmaco, and L. Rivas, "Temporins, small antimicrobial peptides with leishmanicidal activity," *The Journal of Biological Chemistry*, vol. 280, no. 2, pp. 984–990, 2005.
- [11] Q. L. Fivelman, I. S. Adagu, and D. C. Warhurst, "Modified fixed-ratio isobologram method for studying *in vitro* interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of *Plasmodium falciparum*," *Antimicrobial Agents and Chemotherapy*, vol. 48, no. 11, pp. 4097–4102, 2004.
- [12] J. Q. Reimão and A. G. Tempone, "Investigation into *in vitro* anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs," *Memórias do Instituto Oswaldo Cruz*, vol. 106, no. 8, pp. 1032–1038, 2011.
- [13] F. C. Odds, "Synergy, antagonism, and what the checkerboard puts between them," *Journal of Antimicrobial Chemotherapy*, vol. 52, no. 1, article 1, 2003.
- [14] K. Seifert, J. Munday, T. Syeda, and S. L. Croft, "*In vitro* interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against *Leishmania donovani*," *Journal of Antimicrobial Chemotherapy*, vol. 66, no. 4, Article ID dkq542, pp. 850–854, 2011.
- [15] A. G. Tempone, R. A. Mortara, H. F. de Andrade, and J. Q. Reimão, "Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis," *International Journal of Antimicrobial Agents*, vol. 36, no. 2, pp. 159–163, 2010.
- [16] J. Q. Reimão, F. A. Colombo, V. L. Pereira-Chioccola, and A. G. Tempone, "*In vitro* and experimental therapeutic studies of the calcium channel blocker bepridil: detection of viable *Leishmania* (L.) *chagasi* by real-time PCR," *Experimental Parasitology*, vol. 128, no. 2, pp. 111–115, 2011.
- [17] L. M. Johansen, L. E. DeWald, C. J. Shoemaker et al., "A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity," *Science Translational Medicine*, vol. 7, no. 290, pp. 1–14, 2015.
- [18] G. Gehring, K. Rohrmann, N. Atenchong et al., "The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry," *Journal of Antimicrobial Chemotherapy*, vol. 69, no. 8, pp. 2123–2131, 2014.
- [19] A. P. De Souza, H. B. Tanowitz, M. Chandra et al., "Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic *Trypanosoma cruzi* (Brazil strain) infection," *Parasitology Research*, vol. 92, no. 6, pp. 496–501, 2004.
- [20] L. J. Núñez-Vergara, J. A. Squella, S. Bollo-Dragnic et al., "Isradipine and lacidipine: effects *in vivo* and *in vitro* on *Trypanosoma cruzi* epimastigotes," *General Pharmacology*, vol. 30, no. 1, pp. 85–87, 1998.
- [21] L. J. Núñez-Vergara, J. A. Squella, S. Bollo-Dragnic et al., "Nitro aryl 1,4-dihydropyridine derivatives: effects on *Trypanosoma cruzi*," *Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology*, vol. 118, no. 1, pp. 105–111, 1997.
- [22] V. Masseno, S. Muriithi, and A. Nzila, "*In vitro* chemosensitization of *Plasmodium falciparum* to antimalarials by verapamil and probenecid," *Antimicrobial Agents and Chemotherapy*, vol. 53, no. 7, pp. 3131–3134, 2009.
- [23] K. S. Moshal, J. S. Adhikari, K. Bist et al., "Calcium channel antagonist (nifedipine) attenuates *Plasmodium berghei*-specific T cell immune responses in Balb/C mice," *Acta Pathologica Microbiologica et Immunologica Scandinavica*, vol. 115, no. 8, pp. 911–920, 2007.
- [24] A. Ponte-Sucre, Y. Campos, M. Fernandez, H. Moll, and A. Mendoza-León, "*Leishmania* sp.: growth and survival are impaired by ion channel blockers," *Experimental Parasitology*, vol. 88, no. 1, pp. 11–19, 1998.
- [25] Z. Dong, P. Saikumar, J. M. Weinberg, and M. A. Venkatchalam, "Calcium in cell injury and death," *Annual Review of Pathology*, vol. 1, pp. 405–434, 2006.
- [26] G. Benaim, Y. García-Marchán, C. Reyes, G. Uzcanga, and K. Figarella, "Identification of a sphingosine-sensitive Ca²⁺ channel in the plasma membrane of *Leishmania mexicana*," *Biochemical and Biophysical Research Communications*, vol. 430, no. 3, pp. 1091–1096, 2013.
- [27] L. Carvalho, J. R. Luque-Ortega, J. I. Manzano, S. Castany, L. Rivas, and F. Gamarro, "Tafenoquine, an antiplasmodial 8-aminoquinoline, targets *Leishmania* respiratory complex III and induces apoptosis," *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 12, pp. 5344–5351, 2010.
- [28] R. F. S. Menna-Barreto and S. L. de Castro, "The double-edged sword in pathogenic trypanosomatids: the pivotal role of mitochondria in oxidative stress and bioenergetics," *BioMed Research International*, vol. 2014, Article ID 614014, 14 pages, 2014.
- [29] F. Fonseca-Silva, J. D. F. Inacio, M. M. Canto-Cavaleiro, and E. E. Almeida-Amaral, "Reactive oxygen species production and mitochondrial dysfunction contribute to quercetin induced death in *Leishmania amazonensis*," *PLoS ONE*, vol. 6, no. 2, Article ID e14666, pp. 1–7, 2011.
- [30] C.-W. Wang, C.-K. Wang, Y.-J. Chang et al., "Preclinical evaluation on the tumor suppression efficiency and combination drug effects of fermented wheat germ extract in human ovarian carcinoma cells," *Evidence-Based Complementary and Alternative Medicine*, vol. 2015, Article ID 570785, 8 pages, 2015.

- [31] G. Polanco-Hernández, F. Escalante-Erosa, K. García-Sosa et al., “Synergistic effect of lupenone and caryophyllene oxide against *Trypanosoma cruzi*,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 435398, 6 pages, 2013.
- [32] M. Berg, R. García-Hernández, B. Cuypers et al., “Experimental resistance to drug combinations in *Leishmania donovani*: metabolic and phenotypic adaptations,” *Antimicrobial Agents and Chemotherapy*, vol. 59, no. 4, pp. 2242–2255, 2015.
- [33] R. J. Tallarida, “An overview of drug combination analysis with isobolograms,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 319, no. 1, pp. 1–7, 2006.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

